New mRNA drug hopes to restore muscle protein in young boys with DMD
NCT ID NCT07188012
First seen Sep 30, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This early-stage study tests the safety of a new medicine called SPOT-mRNA03 in 6 boys aged 2 to 6 with Duchenne muscular dystrophy (DMD). The treatment aims to help their muscles make dystrophin, a protein missing in DMD. Researchers will check for side effects and measure dystrophin levels in blood and muscle after a single IV infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.